![]() |
市場調查報告書
商品編碼
2065153
穿戴式心電圖監測設備市場預測至2034年-全球產品類型、導線類型、監測類型、技術、應用、最終用戶和地區分析Wearable ECG Monitoring Devices Market Forecasts to 2034 - Global Analysis By Product Type, Lead Type, Monitoring Type, Technology, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球穿戴式心電圖監測設備市場預計將在 2026 年達到 28 億美元,到 2034 年達到 93 億美元,在預測期內以 16.2% 的複合年成長率成長。
穿戴式心電圖監測設備包括各種緊湊型、佩戴於身上的心電圖系統,例如具有心率檢測功能的智慧型手錶、粘貼式心電圖貼片、胸帶式心電圖儀以及口袋大小的個人心電圖記錄儀,這些設備旨在臨床環境之外持續或間斷地記錄心電圖活動。這些設備能夠進行長期心律不整檢測、心房顫動篩檢、心臟風險分層以及心臟事件後監測,並克服了傳統心電圖監測系統的限制。
心房顫動盛行率不斷上升,對持續心臟監測的需求日益成長。
心房顫動是全球最常見的心律不整,且常無症狀,因此,引入能夠捕捉陣發性心房顫動發作的長期連續監測工具至關重要,因為這些發作往往被標準臨床心電圖(ECG)檢查漏診。穿戴式心電圖設備彌補了這個診斷缺口,能夠在患者日常生活中持續數週至數月監測心率,顯著提高心房顫動的檢出率,並有助於及時啟動抗凝血治療以預防中風。心臟科醫師和電生理學家正擴大採用穿戴式式心電圖數據進行風險分層、治療指南和消融術後監測,從而將臨床應用從消費者健康領域擴展到成熟的心臟護理管道。
保險報銷不一致和消費性設備訊號品質挑戰
不同保險公司對穿戴式心電圖 (ECG) 監測數據分析的保險覆蓋範圍仍然不一致,符合條件的適應症、監測期限限制以及醫生索賠代碼的可用性均存在顯著差異。這給了採用消費級穿戴式心電圖數據的臨床項目帶來財務上的不確定性。儘管消費級設備發展迅速,但在實際使用環境中,其訊號品質在運動偽影條件下仍存在局限性,這可能會降低診斷可靠性或造成假陽性警報。穿戴式心電圖準確性和臨床級性能的監管標準尚未完全跟上設備普及的步伐,導致品質保證方面存在模糊之處。這使得臨床醫生在處理來自檢驗設備的數據時難以做出決策。
利用多導聯穿戴式心電圖和人工智慧進行心臟風險分層。
開發一種能夠捕捉全面心臟電向量的多導聯穿戴式心電圖平台,克服當前消費級智慧型手錶單導聯的局限性,蘊藏著巨大的商業性機會。這將使穿戴式裝置能夠實現臨床層級的心律不整特徵分析、ST段分析和肥厚型心肌病篩檢。基於數百萬份心電圖記錄訓練的人工智慧演算法,在多種心律不整外形規格中均能達到與心臟病專家相當的診斷性能,從而為自動化遠端心電圖監測項目鋪平道路,使心臟病專家的專業知識能夠惠及更廣泛的患者群體,而無需相應增加臨床醫生的數量。
對市場飽和和消費性設備數據過載的擔憂
隨著主要消費性電子產品製造商將心率監測功能整合到其智慧智慧型手錶平台中,穿戴式心電圖(ECG)市場的競爭日益激烈,導致價格下降,並對專用醫用級穿戴式心電圖設備的製造商提出了差異化挑戰。在醫療保健系統中,人們擔心處理來自不同裝置平台、檢驗狀態各異的大量穿戴式心電圖資料會對臨床工作流程造成影響。如果業界不建立訊號品質和演算法特異性標準,消費級心臟監測設備的高假陽性率會導致臨床醫生疲勞,從而可能損害穿戴式心臟監測作為臨床工具的可靠性。
新冠疫情提高了人們對病毒性疾病相關心臟併發症(例如心律不整、心肌炎和新冠長期心血管症狀)的認知,從而引發了消費者和臨床醫生對持續心臟監測解決方案的濃厚興趣。疫情期間對臨床接觸的限制加速了遠端心臟監測計畫的普及,穿戴式心電圖設備成為傳統連續型心電圖監測的替代方案,後者需要患者在診所進行佩戴和取回設備。疫情後,對確診心肌炎或心律不整的新冠復健者進行心臟監測,持續推高了監測需求,並擴大了穿戴式心電圖平台的臨床應用範圍。
在預測期內,心電圖貼片細分市場預計將佔據最大的市場佔有率。
預計在預測期內,心電圖貼片市場將佔據最大的市場佔有率,這主要得益於臨床上擴大採用可長時間佩戴的黏性貼片監測儀來檢測不明原因心悸、暈厥或中風患者的陣發性心律不整。最新型心電圖貼片可實現長達14至30天的監測,顯著超越了心電圖監測的性能,從而大幅提高了心房顫動的檢出率。
預計在預測期內,人工智慧整合心電圖監測領域將呈現最高的複合年成長率。
在預測期內,人工智慧整合心電圖監測領域預計將呈現最高的成長率,這主要得益於深度學習演算法的快速發展,這些演算法能夠利用連續的穿戴式心電圖資料流,實現即時心律不整分類、早期疾病檢測和預測性心臟風險評分。人工智慧驅動的心臟監測平台透過支援可擴展的遠端審查程序,顯著提高了監測項目的效率。在這些程序中,演算法會優先處理具有臨床意義的心電圖觀察,供醫師審核。美國食品藥物管理局 (FDA) 已批准人工智慧驅動的穿戴式心電圖診斷功能用於多種心血管適應症,這正在提升其臨床可信度,並擴大其在保險覆蓋範圍內的應用情境。
在預測期內,北美地區預計將佔據最大的市場佔有率。這主要得益於心血管疾病的高發生率、門診心電圖監測的強大醫保覆蓋範圍,以及人工智慧驅動的遠距心電圖監測計畫的前沿臨床應用。美國透過FDA的核准流程,在區域市場確立了主導地位。 FDA已批准多個穿戴式式心電圖平台,使其能夠整合到主流循環系統和基層醫療工作流程中,用於對所有參保患者進行心律不整篩檢和長期心律監測。
在預測期內,亞太地區預計將呈現最高的複合年成長率。這主要得益於心血管疾病負擔的快速加重、智慧型手機普及率的提高(使得行動連線心電圖監測成為可能)以及人們健康意識的增強(推動了消費級心電圖設備的普及)。中國、日本和韓國的政府數位健康計畫正在支持將穿戴式心電圖技術應用於心臟篩檢計畫。中國本土電子製造業的領先地位正在加速價格適中的穿戴式心電圖設備在對價格高度敏感的亞太市場的普及。
According to Stratistics MRC, the Global Wearable ECG Monitoring Devices Market is accounted for $2.8 billion in 2026 and is expected to reach $9.3 billion by 2034, growing at a CAGR of 16.2% during the forecast period. Wearable ECG Monitoring Devices encompass a diverse category of compact, body-worn electrocardiography systems including smartwatches with cardiac sensing capabilities, adhesive ECG patches, chest strap monitors, and pocket-sized personal ECG recorders designed to capture cardiac electrical activity continuously or episodically outside clinical settings. These devices enable long-duration arrhythmia detection, atrial fibrillation screening, cardiac risk stratification, and post-cardiac event monitoring without the constraints of traditional Holter monitor systems.
Rising atrial fibrillation prevalence and demand for continuous cardiac surveillance
Atrial fibrillation the most prevalent cardiac arrhythmia globally frequently presents asymptomatically, creating a significant clinical imperative for extended continuous monitoring tools capable of capturing paroxysmal AF episodes that standard clinical ECGs routinely miss. Wearable ECG devices address this diagnostic gap by enabling weeks or months of continuous rhythm surveillance in the patient's natural environment, substantially improving AF detection rates and supporting timely anticoagulation initiation that prevents stroke. Growing cardiologist and electrophysiologist adoption of wearable ECG data for risk stratification, therapy guidance, and post-ablation monitoring is expanding clinical utilization across established cardiac care pathways beyond consumer wellness applications.
Reimbursement inconsistency and signal quality challenges in consumer-grade devices
Reimbursement coverage for wearable ECG monitoring data interpretation remains inconsistent across payers, with significant variability in covered indications, monitoring duration limits, and physician billing code availability that creates financial uncertainty for clinical programs incorporating consumer wearable ECG data. Consumer-grade devices while improving rapidly exhibit signal quality limitations under real-world motion artifact conditions that can reduce diagnostic confidence and generate false-positive alert burdens. Regulatory standards for wearable ECG accuracy and clinical-grade performance have not fully kept pace with device proliferation, creating quality assurance ambiguities that complicate clinician decision-making regarding data from unvalidated devices.
Multi-lead wearable ECG and AI-powered cardiac risk stratification
The development of multi-lead wearable ECG platforms capable of capturing comprehensive cardiac electrical vectors beyond the single-lead limitation of current consumer smartwatches represents a major commercial opportunity, enabling clinical-grade arrhythmia characterization, ST-segment analysis, and hypertrophic cardiomyopathy screening from wearable form factors. AI algorithms trained on millions of cardiac recordings are achieving cardiologist-equivalent diagnostic performance for multiple arrhythmia types, creating pathways toward automated remote cardiac monitoring programs that scale cardiologist expertise across larger patient populations without proportional clinician workforce expansion.
Competitive market saturation and consumer device data overload concerns
The wearable ECG space is experiencing intensifying competition as major consumer electronics companies integrate cardiac monitoring features into mass-market smartwatch platforms, compressing pricing and creating differentiation challenges for dedicated medical-grade wearable ECG device manufacturers. Healthcare systems are expressing concern regarding the clinical workflow implications of processing large volumes of wearable ECG data from diverse device platforms with variable validation status. Clinician alert fatigue from high false-positive notification rates generated by consumer cardiac monitoring devices risks undermining the credibility of wearable cardiac surveillance as a clinical tool if industry-wide signal quality and algorithm specificity standards are not established.
The COVID-19 pandemic elevated awareness of cardiac complications associated with viral illness, including arrhythmias, myocarditis, and long COVID cardiovascular manifestations, creating heightened consumer and clinician interest in continuous cardiac monitoring solutions. Pandemic-related restrictions on clinical contact accelerated the adoption of remote cardiac monitoring programs using wearable ECG devices as substitutes for traditional Holter monitoring that required in-clinic device application and return. Post-pandemic cardiac surveillance of COVID-19 survivors with documented myocarditis or arrhythmia has created sustained monitoring demand that is expanding the clinical installed base for wearable ECG platforms.
The ECG Patches segment is expected to be the largest during the forecast period
The ECG patches segment is expected to account for the largest market share during the forecast period, driven by strong clinical adoption of long-duration adhesive patch monitors for paroxysmal arrhythmia detection in patients presenting with unexplained palpitations, syncope, or cryptogenic stroke. Extended monitoring durations of 14 to 30 days achievable with modern ECG patches substantially exceed Holter monitor capabilities, improving AF detection yield significantly.
The AI-Integrated ECG Monitoring segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the AI-Integrated ECG Monitoring segment is predicted to witness the highest growth rate, driven by rapid advancement in deep learning algorithms that enable real-time arrhythmia classification, early disease detection, and predictive cardiac risk scoring from continuous wearable ECG data streams. AI-powered cardiac monitoring platforms are enabling scalable remote review programs where algorithms prioritize clinically significant ECG findings for physician review, dramatically improving monitoring program efficiency. FDA clearances for AI-powered wearable ECG diagnostic features across multiple cardiovascular indications are establishing clinical credibility and expanding reimbursable use cases.
During the forecast period, the North America region is expected to hold the largest market share, driven by high cardiovascular disease prevalence, strong reimbursement coverage for ambulatory cardiac monitoring, and leading-edge clinical adoption of AI-powered remote cardiac surveillance programs. The United States drives regional market leadership through FDA clearance pathways that have validated multiple wearable ECG platforms, enabling integration into mainstream cardiology and primary care workflows for arrhythmia screening and long-term rhythm monitoring across insured patient populations.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by rapidly expanding cardiovascular disease burden, growing smartphone penetration enabling mobile-connected cardiac monitoring engagement, and rising consumer health awareness driving direct-to-consumer ECG device adoption. Government digital health programs in China, Japan, and South Korea are supporting cardiac screening initiatives that incorporate wearable ECG technologies. Local electronics manufacturing advantages in China are accelerating affordable wearable ECG device availability across price-sensitive Asia Pacific markets.
Key players in the market
Some of the key players in Wearable ECG Monitoring Devices Market include Apple Inc., Samsung Electronics Co., Ltd., AliveCor, Inc., Medtronic plc, Koninklijke Philips N.V., GE HealthCare Technologies Inc., iRhythm Technologies, Inc., Nihon Kohden Corporation, Omron Healthcare, Inc., Garmin Ltd., Withings S.A., Qardio, Inc., VitalConnect, Inc., Bittium Corporation, and Biotricity Inc.
In March 2026, iRhythm Technologies received expanded FDA clearance for its Zio ECG monitoring platform covering extended monitoring indications for post-cardiac ablation surveillance, broadening its addressable clinical market and enabling electrophysiology programs to standardize wearable monitoring for procedure outcome assessment across their patient populations.
In February 2026, AliveCor announced a strategic partnership with a major health insurer to integrate its KardiaMobile wearable ECG device into a preventive cardiovascular health program targeting high-risk patients, enabling proactive atrial fibrillation screening and remote cardiologist review at population scale within a value-based care framework.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.